DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 022185
» See Plans and Pricing
The generic ingredient in TACLONEX is betamethasone dipropionate; calcipotriene. There are sixty-six drug master file entries for this compound. Additional details are available on the betamethasone dipropionate; calcipotriene profile page.
Summary for 022185
Tradename: | TACLONEX |
Applicant: | Leo Pharma As |
Ingredient: | betamethasone dipropionate; calcipotriene |
Patents: | 2 |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SUSPENSION;TOPICAL | Strength | 0.064%;0.005% | ||||
Approval Date: | May 9, 2008 | TE: | AB | RLD: | Yes | ||||
Regulatory Exclusivity Expiration: | Jan 25, 2023 | ||||||||
Regulatory Exclusivity Use: | |||||||||
Regulatory Exclusivity Expiration: | Jul 25, 2022 | ||||||||
Regulatory Exclusivity Use: | |||||||||
Patent: | Start Trial | Patent Expiration: | Jan 27, 2020 | Product Flag? | Y | Substance Flag? | Delist Request? |
Expired US Patents for NDA 022185
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Leo Pharma As | TACLONEX | betamethasone dipropionate; calcipotriene | SUSPENSION;TOPICAL | 022185-001 | May 9, 2008 | Start Trial | Start Trial |
Leo Pharma As | TACLONEX | betamethasone dipropionate; calcipotriene | SUSPENSION;TOPICAL | 022185-001 | May 9, 2008 | Start Trial | Start Trial |
Leo Pharma As | TACLONEX | betamethasone dipropionate; calcipotriene | SUSPENSION;TOPICAL | 022185-001 | May 9, 2008 | Start Trial | Start Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription